Search

Displaying results 931 - 940 of 10000 in total
  1. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    [T580] Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at … Ergocalciferol is an inactivated vitamin D analog.[A177526] It is synthesized by some plants in the presence of UVB light.

    Mixtures: L-SOLUVIT N, One A Day Tab
  2. Drug

    Ribavirin

    go.drugbank.com/drugs/DB00811
    ApprovedInvestigational

    adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … The inclusion of ribavirin in the combination therapies depend on individual patient's profile, for example if HCV genotype 3 patient has a Y93H genetic variant and compensated cirrhosis.

    Mixtures: Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)
  3. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  4. Indication

    Haemangioma

    go.drugbank.com/conditions/DBCOND0017266
    Drugs: Propranolol · Triamcinolone
  5. Indication

    Obstructive Hypertrophic Cardiomyopathy

    go.drugbank.com/conditions/DBCOND0057747
    Drugs: Ethanol · Propranolol
  6. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening

    Mixtures: AMOXICILLINA E ACIDO CLAVULANICO ZENTIVA LAB, AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S
  7. Drug

    Aluminum hydroxide

    go.drugbank.com/drugs/DB06723
    ApprovedInvestigational

    Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. … Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

    Mixtures: Eno, Eno
  8. Drug

    Talc

    go.drugbank.com/drugs/DB09511
    ApprovedInvestigational

    It is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. … In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.

    Mixtures: OHUI Sun Science Sun Block EX plus Beige, Face It Hd Perfect Bb Spf30 Pa 02Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

    Mixtures: Marcaine E, Marcaine ESynonyms: 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index